Статья
Особенности фармакогенетики дабигатрана: обзор литературы
Дабигатран является высокоэффективным пероральным антикоагулянтом, используемым у пациентов с фибрилляцией предсердий, венозными тромбозами, тромбоэмболией легочной артерии, при ортопедических операциях. Наибольшую роль в его активации и транспорте играют печеночная карбоксилэстераза (CES-1) и P-гликопротеин. К настоящему времени изучены различные генетические полиморфизмы вышеуказанных систем, влияющих на фармакокинетику дабигатрана, такие как rs2244613 (C > A), rs8192935 (T > C) и rs71647871 (G > A), rs1128503 (1236 C > T), rs2032582 (2677 G > T), rs1045642 (3435 C > T) и rs4148738 (G > A) и другие. В то же время убедительных данных, доказывающих необходимость рутинного определения фармакогенетики дабигатрана у пациентов, имеющих показания для его использования в клинической практике нет. С другой стороны, данные литературы нередко противоречивы, поэтому, будущие исследования в этом направлении, вероятно, позволят точнее ответить на поставленный вопрос.
1. Hindric Lin S, Wang Y, Zhang L, et al. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Drug Des Devel Ther. 2019;13: 1527-1533. https://doi.org/10.2147/DDDT.S203112.
2. Ahmed S, Levin V, Malacoff R, et al. Dabigatran: a new chapter in anticoagulation. Cardiovasc Hematol Agents Med Chem. 2012;10(2): 116-23. https://doi.org/10.2174/187152512800388911.
3. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;28;359: j5058. https://doi.org/10.1136/bmj.j5058.
4. Крюков АВ, Сычев ДА, Терещенко ОВ. Фармакогенетические аспекты применения новых оральных антикоагулянтов. Рациональная фармакотерапия в кардиологии. 2017;13(3): 416-421. http://doi.org/10.20996/1819-6446-2017-13-3-416-421.
5. Баранова ЕИ, Кобалава ЖД. Дабигатрана этексилат у пациентов с неклапанной фибрилляцией предсердий: преимущества применения в различных клинических ситуациях. Российский кардиологический журнал. 2019;24(11): 133-141. https://doi.org/10.15829/1560-4071-2019-11-133-141.
6. Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13): 1404-12. https://doi.org/10.1161/CIRCULATIONAHA.112.001233.
7. Dimatteo C, D’Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144: 1-5. https://doi.org/10.1016/j.thromres.2016.05.025.
8. Shi J, Wang X, Nguyen JH, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem. Pharmacol. 2016;119: 76-84. https://doi.org/10.1016/j.bcp.2016.09.003.
9. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost. 2010;103: 572-585. https://doi.org/10.1160/TH09-09- 0659.
10. Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021;11: 37. https://doi.org/10.3390/jpm11010037.
11. Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13): 1250-1259. https://doi.org/10.1001/jama.2017.13883.
12. Bernier M, Lancrerot SL, Rocher F, et al. Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. J. Geriatr. Cardiol. 2019;16: 806-811. https://doi.org/10.11909/j.issn.1671-5411.2019.11.002.
13. European Medicines Agency. Variation assessment report for Multaq, 2012. Accessed 2021-11-13. Available from https://www.ema.europa.eu/documents/variation-report/multaq-h-c-1043-ii-20-epar-assessment-report-variation_en.pdf
14. Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: Review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7: 281-287. https://doi.org/10.1007/s13181-011-0178-y.
15. Ishiguro N, Kishimoto W, Volz A, et al. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers. Drug Metab. Dispos. 2014;42: 250-256. https://doi.org/10.1124/dmd.113.053561.
16. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 2008;36: 386-399. https://doi.org/10.1124/dmd.107.019083.
17. Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74(3): 490-500. https://doi.org/10.1111/j.1365-2125.2012.04218.x.
18. Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers. Med. 2018;11: 127-137. https://doi.org/10.2147/PGPM.S169277.
19. Sychev D, Skripka A, Ryzhikova K, et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020;35(1).
20. Ji Q, Zhang C, Xu Q, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Br J Clin Pharmacol. 2021;87(5): 2247-2255. https://doi.org/10.1111/bcp.14646.
21. Liu Y, Yang C, Qi W, et al. The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects. Pharmgenomics Pers Med. 2021;23;14: 477-485. https://doi.org/10.2147/PGPM. S291723.
22. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70: 189-199. https://doi.org/10.1067/mcp.2001.117412.
23. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13: 481-494. https://doi.org/10.1097/00008571-200308000-00006
24. Xie Q, Xiang Q, Mu G, et al. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. Curr Pharm Des. 2018;24: 3558-3565. https://doi.org/10.2174/1381612824666181018153641.
25. Lahteenmaki J, Vuorinen AL, Pajula J, et al. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clin Pharmacol Ther. 2021;110(3): 768-776. https://doi.org/10.1002/cpt.2316.
26. Gouin-Thibault I, Delavenne X, Blanchard A. et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017 Feb;15(2): 273-283. https://doi.org/10.1111/jth.13577.
27. Gu ZC, Ma XW, Zheng XY, et al. Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect. Front Pharmacol. 2018;15;9: 491. https://doi.org/10.3389/fphar.2018.00491
28. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5): 285-95. https://doi.org/10.2165/00003088-200847050-00001.
29. Stangier J, Rathgen K, Stähle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9(1): 59-68. https://doi.org/10.1007/BF03256595.
30. Wu T, Xia X, Fu J, et al. Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. Medicine (Baltimore). 2020;4;99(36): e22084. https://doi.org/10.1097/MD.0000000000022084.
31. Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;21;39(16): 1330-1393. https://doi.org/10.1093/eurheartj/ehy136.
32. Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9): 1567-75. https://doi.org/10.1124/dmd.110.033696.
33. Савинова АВ, Добродеева ВС, Петрова ММ, и др. Фармакокинетика и фармакогенетика дабигатрана. Рациональная Фармакотерапия в Кардиологии 2021;17(1):146-152. https://doi.org/10.20996/1819-6446-2021-01-04.
34. UniProt. UDP-glucuronosyltransferase 2B15. UniProt Knowledgebase Accessed 2021-11-13. Available from: www.uniprot.org/uniprot/P54855.
35. Shnayder NA, Petrova MM, Shesternya PA, et al. Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines. 2021;22;9(5): 451. https://doi.org/10.3390/biomedicines9050451.
36. He X, Hesse LM, Hazarika S, et al. Evidence for oxazepam as aninvivoprobe of UGT2B15: Oxazepam clearance is reduced by UGT2B15D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009;68: 721-730. https://doi.org/10.1111/j.1365-2125.2009.03519.x.
37. Court MH, Zhu Z, Masse G, et al. Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. J Pharmacol Exp Ther. 2017;362: 431-440. https://doi.org/10.1124/jpet.117.242107.
38. Stringer F, Ploeger BA, De Jongh J, et al. Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar. J Clin Pharmacol. 2013;53: 256-263. https://doi.org/10.1177/0091270012447121.
39. Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics. 2021; online ahead of print. https://doi.org/10.1002/cpt.2350.
40. Zubiaur P, Saiz-Rodríguez M, Ochoa D. et al. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Adv Ther. 2020;37(8): 3537-3550. https://doi.org/10.1007/s12325-020-01414-x.